|Day Low/High||3.90 / 4.00|
|52 Wk Low/High||2.84 / 5.21|
We would consider adding to TherapeuticsMD on the next market decline and booking profits in ON Semiconductor into a rally.
We didn't trade in the model portfolio this week, but several of our holdings made big moves so far this year.
We closed out a number of holdings for big gains in 2016, including McDermott, Cott and CECO Environmental.
We didn't make any trades this week but are keeping 40% of the portfolio in cash to add names as opportunities arise.
We bought more TherapeuticsMD and Yamana Gold using proceeds from the sale of some Orasure shares.
Upcoming webinar highlights how interactive intranets enhance collaboration and drive strategic alignment
We bought shares of TherapeuticsMD but still have a large portion of the portfolio in cash.
"Jive has evolved from a destination to a hub…for access to corporate knowledge"
We booked some profits in Huntington Bancshares and SLM this week and cut our rating on SLM from One to Two.
December 8 webinar discusses how to overcome organizational fragmentation across locations, devices and workstyles
We booked some profits in Synovus Financial and used part of the proceeds to buy more Yamana Gold.
Global research firm names Jive as leading product in recognition of its value-proven digital workplace collaboration hub and breakthrough work graph insights
We sold the rest of our Datalink holdings and will use the proceeds to add a name to our portfolio.
We used this week's declines to add to our position in Jive Software and Sonus Networks.
We believe this stock deserves to trade for more than 3x cash.
The software company's improvement in the third quarter was driven by growth in total billings.
Consensus estimates call for a small third-quarter profit versus a year-earlier loss.
We used this week's declines to add to our positions in Teligent and Sonus Networks.
Financial sponsors are steadily taking a stake in publicly traded companies as they look for creative, sustainable ways to make investments.
We used this week's selloff to take positions in a student loan provider and a generic drug maker.
A rate hike seems likely in December, but not before.
Though the social networking giant's corporate product, previously know as Facebook at Work, might not produce a ton of revenue, there's value in having office workers engaged throughout the day.